SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although Thailand has been fairly effective at controlling the spread of COVID-19, continued disease surveillance and information on antibody response in recovered patients and their close contacts remain necessary in the absence of approved vaccines and antivirals. Here, we examined 217 recovered COVID-19 patients to assess their viral RNA shedding and residual antibodies against SARS-CoV-2. We also evaluated antibodies in blood samples from 308 close contacts of recovered COVID-19 patients. We found that viral RNA remained detectable in 6.6% of recovered COVID-19 cases and up to 105 days. IgM, IgG, and IgA antibodies against SARS-CoV-2 were detected in 13.8%, 88.5%, and 83.4% of the recovered cases 4-12 weeks after disease onset, respectively. Higher levels of antibodies detected were associated with severe illness patients experienced while hospitalized. Fifteen of the 308 contacts (4.9%) of COVID-19 cases tested positive for IgG antibodies, suggesting probable exposure. Viral clearance and the pattern of antibody responses in infected individuals are both crucial for effectively combating SARS-CoV-2. Our study provides additional information on the natural history of this newly emerging disease related to both natural host defenses and antibody duration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
PloS one - 15(2020), 10 vom: 30., Seite e0236905 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chirathaworn, Chintana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 09.11.2020 Date Revised 18.12.2020 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0236905 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316882550 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316882550 | ||
| 003 | DE-627 | ||
| 005 | 20231225162038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0236905 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316882550 | ||
| 035 | |a (NLM)33119712 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chirathaworn, Chintana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although Thailand has been fairly effective at controlling the spread of COVID-19, continued disease surveillance and information on antibody response in recovered patients and their close contacts remain necessary in the absence of approved vaccines and antivirals. Here, we examined 217 recovered COVID-19 patients to assess their viral RNA shedding and residual antibodies against SARS-CoV-2. We also evaluated antibodies in blood samples from 308 close contacts of recovered COVID-19 patients. We found that viral RNA remained detectable in 6.6% of recovered COVID-19 cases and up to 105 days. IgM, IgG, and IgA antibodies against SARS-CoV-2 were detected in 13.8%, 88.5%, and 83.4% of the recovered cases 4-12 weeks after disease onset, respectively. Higher levels of antibodies detected were associated with severe illness patients experienced while hospitalized. Fifteen of the 308 contacts (4.9%) of COVID-19 cases tested positive for IgG antibodies, suggesting probable exposure. Viral clearance and the pattern of antibody responses in infected individuals are both crucial for effectively combating SARS-CoV-2. Our study provides additional information on the natural history of this newly emerging disease related to both natural host defenses and antibody duration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Sripramote, Manit |e verfasserin |4 aut | |
| 700 | 1 | |a Chalongviriyalert, Piti |e verfasserin |4 aut | |
| 700 | 1 | |a Jirajariyavej, Supunnee |e verfasserin |4 aut | |
| 700 | 1 | |a Kiatpanabhikul, Phatharaporn |e verfasserin |4 aut | |
| 700 | 1 | |a Saiyarin, Jatuporn |e verfasserin |4 aut | |
| 700 | 1 | |a Soudon, Chuleekorn |e verfasserin |4 aut | |
| 700 | 1 | |a Thienfaidee, Orawan |e verfasserin |4 aut | |
| 700 | 1 | |a Palakawong Na Ayuthaya, Thitisan |e verfasserin |4 aut | |
| 700 | 1 | |a Brukesawan, Chantapat |e verfasserin |4 aut | |
| 700 | 1 | |a Chaiwanichsiri, Dootchai |e verfasserin |4 aut | |
| 700 | 1 | |a Intharasongkroh, Duangnapa |e verfasserin |4 aut | |
| 700 | 1 | |a Wanlapakorn, Nasamon |e verfasserin |4 aut | |
| 700 | 1 | |a Chansaenroj, Jira |e verfasserin |4 aut | |
| 700 | 1 | |a Puenpa, Jiratchaya |e verfasserin |4 aut | |
| 700 | 1 | |a Yorsaeng, Ritthideach |e verfasserin |4 aut | |
| 700 | 1 | |a Thitithanyanont, Arunee |e verfasserin |4 aut | |
| 700 | 1 | |a Kitphati, Rungrueng |e verfasserin |4 aut | |
| 700 | 1 | |a Mungaomklang, Anek |e verfasserin |4 aut | |
| 700 | 1 | |a Nagavajara, Pijaya |e verfasserin |4 aut | |
| 700 | 1 | |a Poovorawan, Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 15(2020), 10 vom: 30., Seite e0236905 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:10 |g day:30 |g pages:e0236905 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0236905 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 10 |b 30 |h e0236905 | ||